Grant: CIHR Fellowship
Direct Payment
$150,000.00
Gut Hormones and the Resolution of Diabetes after Bariatric Surgery
EF 2009-10
Résumé
The 2004 Canadian Consumer Health Survey estimated that 5.5 million Canadians aged 18 or older are obese and another 8.6 million overweight. The health consequences of obesity are well known, especially with respect to the risk of type II diabetes. Currently over 3 million Canadians have diabetes and that number is expected to reach 3.7 million by the year 2020, with an estimated cost to the Canadian health care system of nearly 17 billion annually. Bariatric surgery is currently the only effective treatment for morbid obesity, and it prolongs life as well as ameliorating obesity and diabetes. Operated patients can expect to lose 75% or more of their excess fat within 6 months after surgery, and the weight loss is likely to be maintained for the rest of the patient's life. The effect of bariatric surgery on diabetes is rapid, with some patients leaving the hospital without the need for further diabetes medication. The rapidity of this effect has led to the hypothesis that bariatric surgery reduces diabetes independent of weight loss, but the underlying mechanism has not been identified. The frequency of bariatric surgeries has increased in Canada every year over the past decade, and the current average wait time is 5 years. Understanding the mechanism(s) that produce the benefits of bariatric surgery is critical for three reasons. First, it is our responsibility to understand how we are affecting these patients. Second, mechanistic studies are critical for developing less invasive and more cost-effective procedures. Finally, mechanistic studies are critical for identifying those patients most likely to benefit from this treatment.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ohio, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
203825
Name
Chambers Adam
Region
Ohio
Country
United States of America
Orgtype
Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Gut Hormones and the Resolution of Diabetes after Bariatric Surgery
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bariatric Surgery; Body Weight; Diabetes; Ghrelin; Glp-1; Goat; Insulin Clamp; Obesity; Roux-En-Y Gastric Bypass; Vertical Sleeve Gastrectomy
Abstract
The 2004 Canadian Consumer Health Survey estimated that 5.5 million Canadians aged 18 or older are obese and another 8.6 million overweight. The health consequences of obesity are well known, especially with respect to the risk of type II diabetes. Currently over 3 million Canadians have diabetes and that number is expected to reach 3.7 million by the year 2020, with an estimated cost to the Canadian health care system of nearly 17 billion annually. Bariatric surgery is currently the only effective treatment for morbid obesity, and it prolongs life as well as ameliorating obesity and diabetes. Operated patients can expect to lose 75% or more of their excess fat within 6 months after surgery, and the weight loss is likely to be maintained for the rest of the patient's life. The effect of bariatric surgery on diabetes is rapid, with some patients leaving the hospital without the need for further diabetes medication. The rapidity of this effect has led to the hypothesis that bariatric surgery reduces diabetes independent of weight loss, but the underlying mechanism has not been identified. The frequency of bariatric surgeries has increased in Canada every year over the past decade, and the current average wait time is 5 years. Understanding the mechanism(s) that produce the benefits of bariatric surgery is critical for three reasons. First, it is our responsibility to understand how we are affecting these patients. Second, mechanistic studies are critical for developing less invasive and more cost-effective procedures. Finally, mechanistic studies are critical for identifying those patients most likely to benefit from this treatment.
Competitiondate
201002
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chambers, Adam
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~